Give the Gift of Hope this Holiday Season! Support PWSA | USA's 2025 Angel Drive. Donate Now

Category: Blog

You’re Invited: Webinar on Prader-Willi Syndrome and VYKAT™ XR (diazoxide choline)

Note: This event is hosted by Soleno Therapeutics and shared by PWSA | USA as an educational opportunity for the Prader-Willi syndrome (PWS) community. Families, caregivers, and professionals are invited to join Soleno Therapeutics for an upcoming educational webinar discussing Prader-Willi syndrome and VYKAT™ XR (diazoxide choline), a treatment for individuals 4 years and older...

Soleno Therapeutics to Invest $5 Million in Research Toward a Potential Cure for Prader-Willi Syndrome

PWSA | USA is excited to celebrate a powerful new commitment from Soleno Therapeutics, a company already making history in the Prader-Willi syndrome (PWS) community. Following the FDA approval of VYKAT™ XR (diazoxide choline extended-release tablets), the first-ever treatment for hyperphagia in PWS, Soleno has announced plans to invest up to $5 million in grant...

Calling Indiana PWS Families!

The Indiana Medicaid Drug Utilization Review (DUR) Board Meeting will be meeting October 17, 2025, starting at 10:00 AM EST. Here’s how you can help: The Indiana Medicaid DUR Board needs to hear directly from you – the parents, caregivers, and family members who understand the real-life impact of hyperphagia (excessive hunger) in PWS. One...

HERO Clinical Trial for ARD-101 Now Enrolling Open-Label Extension (OLE)

Earlier this year, Aardvark Therapeutics launched HERO, a global Phase 3 clinical trial investigating ARD-101, an innovative, orally administered treatment designed to help reduce hyperphagia (excessive hunger) and food-seeking behaviors in individuals with Prader-Willi syndrome (PWS). All patients who have completed treatment on the AVK-101-301 study through Week 12/End of Treatment will have the option to join...

Understanding P&T Committees and DUR Boards

Why do P&T Committees and DUR Boards Matter for PWS Treatments? For families living with Prader-Willi syndrome, access to new therapies isn’t just about FDA approval. Once a drug is approved, there’s another critical step that determines whether patients can actually receive treatment: coverage decisions made by Pharmacy & Therapeutics (P&T) Committees and Drug Utilization...

Acadia Shares Results of Phase 3 Carbetocin Trial: Primary Endpoint Not Met

On Wednesday, September 24, 2025, Acadia Pharmaceuticals shared an update on their Phase 3 COMPASS PWS trial, which evaluated intranasal carbetocin (ACP-101) for hyperphagia (excessive hunger) in children and adults with Prader-Willi syndrome (PWS). The trial did not meet its primary endpoint of improving scores on the Hyperphagia Questionnaire for Clinical Trials (HQ-CT) from baseline...

Scroll to top